Mentioned On
Episode Mentions
Bloomberg Intelligence · Jul 16, 2026
Lilly Strikes $3.8 Billion Deal for Psychedelic Drugmaker
“Psychedelic drug development company competing in treatment-resistant depression space”
Psychedelic Drug Development and RegulationEli Lilly M&A Strategy and Contingent Value RightsPCSK9 Inhibitors and Cholesterol Management
View Analysis
Stock Movers · Jul 16, 2026
JB Hunt Gains, GH Research Rises, Abbott Laboratories Surges on 2026 Profit Guidance Raise
“Psychedelic drug maker gained on investor optimism following Eli Lilly's $3.8 billion acquisition of Ty Beckley, signaling large pharma interest in the sector.”
Abbott Laboratories earnings and guidance raiseMedical device industry strengthDiabetes care market performance
View Analysis